EU Review of Pharmaceutical Incentives: Recommendations for Change
In 2016, the European Council decided it was time for a review of the incentives that the EU provides to companies that develop new...
Wrapping Up 2017 – some noteworthy medicines law and policy events.
2017 was a significant year for access to medicines and other medicines policy related events. Here are a few highlights of the last 12...
Urgent collective action to meet the challenge of this pandemic crisis: a coronavirus related...
The Director-General of the World Health Organization (WHO), Tedros Adhanom Ghebreyesus, first described the present coronavirus (COVID-19) outbreak as a pandemic on the 11th...
The Urgency of Compulsory Licensing Provision for Transfer of Technology in the Pandemic Treaty:...
Guest blog by Ronald Eberhard
The Intergovernmental Negotiating Body, established by the World Health Assembly, aims to draft a global pandemic prevention, preparedness, and response...
WHO Members meet to finalise the Pathogen Access and Benefit Sharing Instrument
In May 2025, the WHO member states adopted the Pandemic Agreement, but they left the work to establish an instrument for Pathogen Access and...
Commission report on competition enforcement in the pharmaceutical sector
Guest author Jacquelyn D. Veraldi is Assistant Professor of European Law at the University of Groningen. Guest author Tais A. Ruiz Palacios is a...
Advanced Purchase Agreements for Covid-19 Vaccines: Do they ensure Global Public Good?
Advanced Purchase Agreements (APAs) were part of a strategy to provide upfront financing for Covid-19 vaccines and to accelerate their development and availability. Since...
Wrapping up 2019 – Noteworthy Medicines Law and Policy Events
2019 had its share of noteworthy medicines law and policy events. It was also a year that saw eye-popping new levels of pharmaceutical pricing....
Pharmaceutical Accountability Foundation meets AbbVie in court, looking to advance its pricing case
“The value of a human life is infinite, but unfortunately our healthcare budget is not,” said former Dutch Health Minister Bruno Bruins, quoted by...
Some Surprises in the European Commission’s New Intellectual Property Strategy
The European Commission's new intellectual property (IP) strategy is out and it holds a number of surprises for access to medicines. After restating the...